Global Cellular Immunotherapy Market Share Report 2024, Forecast To 2033
9 Jan, 2024
Experiencing rapid expansion, the cellular immunotherapy market is set to rise from $4.99 billion in 2023 to $5.78 billion in 2024, presenting a CAGR of 15.9%. Historical growth results from advancements in cancer treatment and clinical successes. The forecast anticipates continued growth, reaching $9.95 billion in 2028, fueled by expanded applications, improved manufacturing, and robust research funding.
Global Cellular Immunotherapy Market Key Driver
Growth in the cellular immunotherapy market is attributed to increasing research and successful clinical trials. Companies are actively developing new cellular immunotherapies for various diseases. According to the Cancer Research Institute, the immuno-oncology pipeline featured 2,756 active cell therapy drugs in April 2022, indicating a 36% increase. The accelerated development of cellular immunotherapy is expected to boost the market, generating higher revenues in the forecast period.
Get A Free Sample Of The Global Cellular Immunotherapy Market ReportGlobal Cellular Immunotherapy Market Segments
The cellular immunotherapy market covered in this report is segmented –
1) By Therapy: Tumour-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy
2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications
3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumour, Lung Cancer, Other Applications
By Geography: The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the cellular immunotherapy market in 2023. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Cellular Immunotherapy Industry Players
Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation
Get The Full Global Cellular Immunotherapy Market Report
Cellular Immunotherapy Market Overview
Cellular immunotherapy refers to a sort of immunotherapy in which a patient receives T cells, an immune cell, to aid the body in fighting diseases like cancer. It is a cutting-edge kind of treatment that uses the body's immune system to combat cancer.
Cellular Immunotherapy Global Market Report 2023 provides data on the global cellular immunotherapy market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The cellular immunotherapy market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.